Paroxysmal Supraventricular Tachycardia Clinical Trial
— ZFA-PSVTOfficial title:
Multi-center, Controlled Trial to Compare the Feasibility, Safety and Efficacy of Zero-fluoroscopic Approach With Fluoroscopic Approach for the Ablation of Paroxysmal Supraventricular Tachycardia
Verified date | November 2023 |
Source | Tongji Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study is aimed to compare the feasibility, safety and efficacy of a zero-fluoroscopic approach using Ensite NavX with conventional fluoroscopic approach using Ensite NavX plus fluoroscopy for the ablation of paroxysmal supraventricular tachycardia.
Status | Completed |
Enrollment | 3060 |
Est. completion date | December 2018 |
Est. primary completion date | February 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 12 Years to 90 Years |
Eligibility | Inclusion Criteria: - Atrioventricular Nodal Reentrant Tachycardia - Atrioventricular Reentrant Tachycardia Exclusion Criteria: - Atrial Tachycardia - Organic supraventricular tachycardia |
Country | Name | City | State |
---|---|---|---|
China | Tongji Hospital | Wuhan | Hubei |
Lead Sponsor | Collaborator |
---|---|
Tongji Hospital | Beijing Anzhen Hospital, Chinese Academy of Medical Sciences, Fuwai Hospital, First Affiliated Hospital of Guangxi Medical University, First Affiliated Hospital, Sun Yat-Sen University, Guangdong Provincial People's Hospital, Morristown Memorial Hospital, Ningbo No. 1 Hospital, Xiangyang Central Hospital |
China,
Anselmino M, Sillano D, Casolati D, Ferraris F, Scaglione M, Gaita F. A new electrophysiology era: zero fluoroscopy. J Cardiovasc Med (Hagerstown). 2013 Mar;14(3):221-7. doi: 10.2459/JCM.0b013e3283536555. — View Citation
Brown KR, Rzucidlo E. Acute and chronic radiation injury. J Vasc Surg. 2011 Jan;53(1 Suppl):15S-21S. doi: 10.1016/j.jvs.2010.06.175. Epub 2010 Sep 16. Erratum In: J Vasc Surg. 2012 Feb;55(2):627. — View Citation
Lim PB, Robb D, Lambiase PD. Electrophysiology and ablation of arrhythmias. Br J Hosp Med (Lond). 2012 Jun;73(6):312-8. doi: 10.12968/hmed.2012.73.6.312. — View Citation
Mobinizadeh M, Arabloo J, Hamouzadeh P, Akbari Sari A. A systematic review of the effectiveness of catheter ablation NavX mapping system for treatment of the cardiac arrhythmia. Med J Islam Repub Iran. 2015 Mar 10;29:189. eCollection 2015. — View Citation
Wang Y, Patel D, Wang DW, Yan JT, Hsia HH, Liu H, Zhao CX, Zuo HJ, Wang DW. beta1-Adrenoceptor blocker aggravated ventricular arrhythmia. Pacing Clin Electrophysiol. 2013 Nov;36(11):1348-56. doi: 10.1111/pace.12196. Epub 2013 Jun 10. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Procedural success rate | Procedural success for AVNRT was defined as the absence of inducible tachycardia either under basal condition or under isoproterenol stimulation. Procedural success for AVRT was defined as the non-inducibility of tachycardia, loss of pre-excitation (if manifest), loss of retrograde accessory pathway conduction and transient atrioventricular block induced by intravenous adenosine. | one year | |
Secondary | Complications | Complications were defined as pseudoaneurysm, arterialvenous fistula, pneumothorax, second- or third-degree atrioventricular block, cardiac tamponade, or other serious complications requiring intervention. | one year | |
Secondary | Immediate success rate | Procedural success for AVNRT was defined as the absence of inducible tachycardia either under basal condition or under isoproterenol stimulation. Procedural success for AVRT was defined as the non-inducibility of tachycardia, loss of pre-excitation (if manifest), loss of retrograde accessory pathway conduction and transient atrioventricular block induced by intravenous adenosine. | one day | |
Secondary | Recurrence Rate | 2. An ECG and electrophysiology study would be performed to rule out recurrence when the patients had suspicious symptoms or signs. | 1 year | |
Secondary | Total procedure time | Procedure time (in minutes) was defined as the interval from the beginning of local anesthesia to extraction of all femoral venous sheaths at the end of the procedure. Total ablation time was calculated in seconds but time for tentative ablation was not taken into account. | one day | |
Secondary | Fluoroscopy time | 2. Fluoroscopy time (in minutes) was defined as thetotal duration of exposure during the procedure. | one day |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04072835 -
Safety Study of Etripamil Nasal Spray for Patients With Paroxysmal Supraventricular Tachycardia. NODE-303
|
Phase 3 | |
Completed |
NCT01655316 -
Oral Verapamil in Acute Paroxysmal Supra Ventricular Tachycardia(PSVT) Recurrence Control
|
Phase 4 | |
Completed |
NCT05770921 -
Pulsed Field Ablation for Paroxysmal Supraventricular Tachycardia(PSVT)
|
N/A | |
Active, not recruiting |
NCT05820035 -
A Multicenter Study of Pulsed Field Ablation for Paroxysmal Supraventricular Tachycardia
|
N/A | |
Not yet recruiting |
NCT06327425 -
MCG for Localization of Tachyarrhythmia's Origin
|
N/A | |
Recruiting |
NCT05410860 -
Efficacy and Safety Study of Etripamil Nasal Spray Self-Administration for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia
|
Phase 3 | |
Completed |
NCT03464019 -
Efficacy and Safety of Etripamil for the Termination of Spontaneous Paroxymal Supraventricular Tachycardia (PSVT). NODE 301 [Part 1 and Part 2 (RAPID Study)]
|
Phase 3 | |
Completed |
NCT04215640 -
Radiofrequency Ablation of Paroxysmal Supraventricular Tachycardia Using a Novel Catheter Equipped With Mini Electrodes
|
N/A | |
Completed |
NCT03348436 -
Study on Left Atrial Function of Paroxysmal Supraventricular Tachycardia After Radiofrequency Ablation
|
N/A | |
Enrolling by invitation |
NCT04952610 -
Etripamil Nasal Spray in Patients With Paroxysmal Supraventricular Tachycardia
|
Phase 3 | |
Recruiting |
NCT05763953 -
The NODE-202 Study (Study of Etripamil Nasal Spray in Pediatric Patients)
|
Phase 2 | |
Terminated |
NCT03635996 -
Safety Study of Intranasal Etripamil for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia (PSVT). NODE-302
|
Phase 3 |